NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for lung cancer: combo therapy targets tough-to-treat tumors
Disease control Recruiting nowThis study tests whether adding an investigational drug (telisotuzumab adizutecan) to the standard treatment osimertinib works better than standard care alone for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer). About 854…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New hope for lung cancer patients with HER2 mutation: phase 3 trial launches
Disease control Recruiting nowThis study compares a new drug, BL-M07D1, to standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific HER2 gene change. About 440 adults will be randomly assigned to one of the two treatments. The goal is to see if the new drug helps peopl…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New hope for lung cancer: experimental drug rilvegostomig takes on standard therapy
Disease control Recruiting nowThis study compares a new drug, rilvegostomig, against the standard immunotherapy pembrolizumab, both given with chemotherapy, as a first treatment for people with advanced non-squamous non-small cell lung cancer that has spread and has a protein called PD-L1. About 878 participa…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New combo therapy targets hard-to-treat lung cancer
Disease control Recruiting nowThis study tests whether combining two drugs, BL-M07D1 and pembrolizumab, can shrink tumors in people with advanced HER2-positive non-small cell lung cancer. About 80 adults with cancer that has spread or cannot be removed by surgery will receive the treatment. The goal is to see…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Could a cheaper keytruda copy work just as well for lung cancer?
Disease control Recruiting nowThis study tests whether MB12, a proposed copy of the cancer drug Keytruda, works as well as the original when combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer. About 726 adults with stage IV disease who haven't had prior treatment will …
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
Brazilian lung cancer study seeks Real-World treatment clues
Knowledge-focused Recruiting nowThis study looks back at medical records of 250 adults in Brazil with advanced non-squamous non-small cell lung cancer. Researchers want to see what treatments patients receive after platinum-based chemotherapy stops working. The goal is to describe real-world patient characteris…
Matched conditions: NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 22, 2026 14:04 UTC